|
|
|
|
|
Methohexital
drug data and news
Methohexital drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Methohexital | ||
| Brand Names/Synonyms | Brevital; Brevital Sodium; Brietal; Methodrexitone; Methohexital; Methohexitone | ||
| Indication | Indicated for use as an intravenous anaesthetic. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Methohexital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation. | ||
| Mechanism Of Action | Methohexital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. | ||
| Methohexital News (When available) |
Impact of ECT on Health-Related Quality of Life and Function in ... Apr 29, 2006 | ||
| Dosage Forms | POWDER FOR SOLUTION | ||
| Drug_Category | Anesthetics; Barbiturates; ATC:N01AF01; ATC:N05CA15 | ||
| Absorption | The absolute bioavailability of rectal methohexital sodium is 17%. | ||
| Interactions |
-->Interactions for Methohexital: Prior chronic administration of barbiturates or phenytoin (e.g. for seizure disorder) appears to reduce the effectiveness of Brevital Sodium. Barbiturates may influence the metabolism of other concomitantly used drugs, such as phentyoin, halothane, anticoagulants, corticosteroids, ethyl alcohol, and propylene glycol-containing solutions. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 1-methyl-5-(1-methylpent-2-ynyl)-5-prop-2-enyl-hexahydropyrimidine-2,4,6-trione | ||
| Chemical Formula | C14H18N2O3 | ||
| Molecular Weight | 262.304 g/mol | ||
| Smiles String | CCC#CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 1.724 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Metabolism occurs in the liver through demethylation and oxidation. Side-chain oxidation is the most important biotransformation involved in termination of biologic activity. | ||
| Half Life | 5.6 ± 2.7 minutes | ||
| Protein Binding [%] | 73% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Methohexital.html http://www.rxlist.com/cgi/generic3/methohexital.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00058 | ||
| CAS Registry Number | 151-83-7 | ||
| KEGG Compound ID | C07844 | ||
| PubChem ID | SID:10046 | ||
| PharmGKB ID | PA450426 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 128678 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |